SUDESH K. MAHAJAN, M.D.; ALI A. ABBASI, M.D.; ANANDA S. PRASAD, M.D., Ph.D.; PARVIZ RABBANI, Ph.D.; WILLIAM A. BRIGGS, M.D.; FRANKLIN D. McDONALD, M.D.
Zinc deficiency may account for the persistence of gonadal dysfunction in a majority of uremic men despite adequate dialysis. Twenty stable patients having hemodialysis three times a week completed a double-blind trial using either 50 mg of elemental zinc as zinc acetate (10 patients) or placebo (10 patients), orally. At the end of the 6-month study period, a significant increase in the mean (± SE) plasma zinc (75 ± 2 µg/dL to 100 ± 2 µg/dL, p < 0.001), serum testosterone (2.8 ± 0.3 ng/dL to 5.2 ± 0.5 ng/mL, p < 0.001), and sperm count (30 ± 3 million/mL to 63 ± 5 million/mL, p < 0.001) occurred in the zinc-treated group, but not in those receiving the placebo. The zinc-treated group also had a significant fall in serum luteinizing hormone (92 ± 10 mIU/mL to 49 ± 26 mIU/mL, p < 0.005) and follicle stimulating hormone (45 ± 9 mIU/mL to 25 ± 7 mIU/mL, p < 0.05), not seen in the placebo group. Patients receiving zinc had an improvement in potency, libido, and frequency of intercourse not found in the placebo group. These results suggest that zinc deficiency is a reversible cause of gonadal dysfunction in patients having regular hemodialysis.
Learn more about subscription options.
Register Now for a free account.
MAHAJAN SK, ABBASI AA, PRASAD AS, RABBANI P, BRIGGS WA, McDONALD FD. Effect of Oral Zinc Therapy on Gonadal Function in Hemodialysis Patients: A Double-Blind Study. Ann Intern Med. 1982;97:357-361. doi: 10.7326/0003-4819-97-3-357
Download citation file:
Published: Ann Intern Med. 1982;97(3):357-361.
Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only